INSIDE PHARMA

INSIDE PHARMA

Share this post

INSIDE PHARMA
INSIDE PHARMA
Point of Care Manufacturing: the Trojan Horse to introduce gene therapies

Point of Care Manufacturing: the Trojan Horse to introduce gene therapies

Another one you couldn't make up

Hedley Rees's avatar
Hedley Rees
Jun 20, 2023
∙ Paid
23

Share this post

INSIDE PHARMA
INSIDE PHARMA
Point of Care Manufacturing: the Trojan Horse to introduce gene therapies
17
2
Share

UK Government gives the green light

Whether you know it or not, UK Government, through MHRA, now allows hospitals to manufacture at point of care, but only for advanced therapies, which include gene therapies. This is the announcement:

UK to introduce first-of-its-kind framework to make it easier to manufacture innovative medicines at the point of care.

It claims:

“The establishment of a regulatory framework for POC manufacturing would bring a range of benefits to patients, healthcare professionals and innovators.”

“The UK will be the first country to introduce a tailored framework for the regulation of innovative products manufactured at the point where a patient receives care, the Medicines and Healthcare products Regulatory Agency (MHRA) has announced today. This will mean that new medicines with very short shelf lives and highly personalised medicines can more easily be made in or near a hospital setting or ambulance and can get to the patients who need them much more quickly.”

It’s har…

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Hedley Rees
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share